
News|Articles|October 10, 2025
A "One-Two Punch" to Innovation? The Most Favored Nation Order and Broader US Drug Pricing Reform
Author(s)Rose McNulty
Fact checked by: Maggie L. Shaw
Explore the implications of the Most Favored Nation Order on US drug pricing reform and its potential impact on patient access and innovation.
Advertisement
Advertisement
Drug pricing reform is a complex undertaking, and developments related to the recent Most Favored Nation (MFN) executive order give insight into how the initiative may fit into broader drug pricing reform in the US. This was the basis of discussion at a webinar hosted by MJH Life Sciences® titled “Most Favored Nation Order: Legal Battles, Market Shifts, and the Future of Drug Pricing Reform.”
Related to this article

Medicare Advantage exits, rising ACA premiums, a Medicare for America bill, and a Medicaid work rule ruling frame health policy on Election Day.

The EEOC is reportedly preparing to narrow Pregnant Workers Fairness Act rules; no revised rule has been published as of yet.

An economic evaluation found nontargeted hepatitis C screening in emergency departments offered the greatest health benefit at a cost-effective price.

The Community Oncology Alliance said final 2027 Medicare payment rules address longstanding gaps between hospital and community practice reimbursement, but it urged Congress to stop another physician pay cut and to fix how the Inflation Reduction Act will pay practices for Part B drugs.

Clinicians at an AJMC roundtable in Cleveland said Medicare's GLP-1 Bridge came late and that cost and capacity gaps persist.

Pharmacists outline new oncologic therapeutics, from pancreatic cancer to myeloma, and what high prices and crowded markets mean for payers.

Antimicrobial resistance in bronchiectasis and cystic fibrosis varied widely in a study spanning 11 centers on 3 continents.
Advertisement
Advertisement

